Multiple Sclerosis Treatment in New Delhi

Confirmation needs clinical attacks or progression plus MRI evidence of lesions separated in space and time. Blood tests for AQP4 and MOG antibodies help exclude NMOSD and related disorders before starting long-term therapy.

No. Neuromyelitis optica spectrum disorder is a distinct antibody-mediated disease with different relapse risks and treatments. Misclassifying NMO as MS can lead to the wrong immunotherapy and worse outcomes.

Most relapsing MS patients benefit from disease-modifying therapy. Choice and duration depend on disease activity, MRI changes, side-effect profile and pregnancy plans — decisions are individualised at follow-up.

New or worsening neurological symptoms lasting more than twenty-four hours may be a relapse. Your neurologist may prescribe high-dose corticosteroids after excluding infection and arranging urgent imaging when needed.

Yes — some disease-modifying drugs must be stopped before conception. Discuss family planning early so therapy can be timed safely without leaving disease uncontrolled for long periods.

Many patients remain mobile for decades with early treatment and rehabilitation. Disability risk rises with untreated active disease, smoking and poor relapse control — proactive care improves the outlook.

Low vitamin D is common and correcting deficiency is reasonable as part of overall care. It does not replace disease-modifying therapy when MRI or clinical activity shows ongoing inflammation.

After starting or changing therapy, MRI is often repeated within six to twelve months to check for new lesions, then periodically based on clinical stability. Your neurologist sets the schedule for your case.